Skyline will use TrovaGene's nucleophosmin protein mutation, which is found in around 35 percent of acute myeloid leukemia patients and is associated with good disease prognosis, in its Affymetrix-manufactured AMLprofiler in vitro diagnostic.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.
